



Photo above: the EAVI2020 consortium at the 1st annual meeting in Barcelona, 11 November 2016

## Have a look at EAVI2020's published papers on year 1!

1 February 2017

After one year of research, EAVI2020 has published four articles.

The papers have been published by teams from University of Oxford, King's College London, Instituto de Salud Carlos III and Academisch Medisch Centrum, and they are available online:

- HIV-1 Glycan Density Drives the Persistence of the Mannose Patch within an Infected Individual. DOI: 10.1128/JVI.01542-16.
- Detection of Broadly Neutralizing Activity within the First Months of HIV-1 Infection. DOI: 10.1128/JVI.00049-16.
- An HIV-1 antibody from an elite neutralizer implicates the fusion peptide as a site of vulnerability. DOI: 10.1038/nmicrobiol.2016.199.
- Novel Conserved-region T-cell Mosaic Vaccine With High Global HIV-1 Coverage Is Recognized by Protective Responses in Untreated Infection. DOI: 10.1038/mt.2016.3.



### EAVI2020 Key facts

23 worldwide institutions

€23 million euro

5 years

EU Horizon2020 funding

Objective:

To develop novel candidate vaccines that can be taken through to human trials within five years.

### EAVI2020 useful links

[www.eavi2020.eu](http://www.eavi2020.eu)



Like us on Facebook  
[www.facebook.com/eavi2020](http://www.facebook.com/eavi2020)



LinkedIn  
[www.linkedin.com/company/eavi2020](http://www.linkedin.com/company/eavi2020)



Twitter  
[www.twitter.com/eavi2020](http://www.twitter.com/eavi2020)



# EAVI2020 Newsletter

## Prof Shattock at GESIDA's annual meeting.

30 November 2016

Prof Robin Shattock (Imperial) presented at the plenary session of the Spanish AIDS society (GESIDA)'s AIDS Research Network (RIS) annual meeting in San Sebastian, Spain, 30th November 2016.

Prof Shattock was also interviewed by GESIDA on his work on Neutralizing Antibodies for prevention and treatment of HIV infection and the progress of EAVI2020's work in its first year of research. If you would like to read the full interview, you will find it here.

For a summary video of the event, please click here.

If you speak Spanish, you can have a look at this article too: Los nuevos horizontes de los anticuerpos neutralizantes.

## Marit van Gils wins the Beijerinck Premium award from the Royal Dutch Academy of Science.

1 February 2017

The Beijerinck Premium is intended to encourage virology research and is awarded every two years.

Marit van Gils is a post-doc researcher at Academisch Medisch Centrum and is part of the team working in EAVI2020. This award is given to young post-doc researchers in recognition of outstanding virus-related research at a Dutch scientific organisation.

The ceremony will take place on the 3rd March 2017.

### More information

For more information please go to the Beijerinck Premium's website.



Robin Shattock at GESIDA, 30 Nov 2016

## EAVI2020 at upcoming events

Keystone Symposia on Molecular and Cellular Biogoly | 26-30 March 2017, Keystone, US.

9th IAS Conference on HIV Science (IAS 2017) | 23-26 July 2017, Paris, France.

Cent Gardes Conference | 21-25 October 2017, Paris, France.



Tomas Hanke at the 2016 Keystone Symposia on HIV Vaccines

### Links to talks by EAVI2020 at the 2016 Keystone Symposia on HIV Vaccines

- Novel Conserved-region T-cell Mosaic Vaccine with High Global HIV-1 Coverage Is Recognized by Protective Responses in Untreated Infection | Tomas Hanke, University of Oxford;
- A broadly neutralizing antibody from an elite neutralizer targets a novel site at the gp120-gp41 interface | Marit van Gils, Academisch Medisch Centrum;
- Link to all videos here.